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Colorectal cancer (CRC) was ranked third and second of all cancers 
affecting men and women, respectively, with metastases representing the 
first cause of death and defining the stage IV of the disease, characterized 
by a relatively short overall survival. It has been recently demonstrated that 
epithelial to mesenchymal transition (EMT), a physiological mechanism 
involved in embryonic development and tissue remodelling, could also play 
a critical role in invasion and metastasis of many types of cancer, including 
CRC. During EMT, epithelial cancer cells acquire not only mesenchymal 
traits, but also a stem cell-like phenotype, with ability of self-renewal, 
unlimited proliferation and resistance to apoptosis.  
On this point of view, it is of significant and primary interest for cancer 
biomedical research to identify genes and proteins mainly involved in EMT 
and stemness, since they could represent good potential targets for therapy 
and predictive/prognostic molecular biomarkers. 
During this work we isolated primary mesenchymal colorectal cancer cells 
from CRC patients, and demonstrated that they expressed epithelial (E-
Cadherin and Cytokeratins), mesenchymal (N-Cadherin and Vimentin) and 
stemness markers, together with high level of epithelial-mesenchymal 
transition-transcription factors (EMT-TFs) (Snail and Twist). These primary 
cell cultures were isolated from adenocarcinomas, which are epithelial 
tumours, thus our data suggested that these cells were epithelial cells 
undergone EMT. 
GSK-3β is a multifunctional serine/threonine kinase and an important 
regulator of cell survival by regulating PI3K, MAPK and WNT pathways.  
It may act as anti- or pro-apoptotic factor in a cell‑specific manner; in colon 
and pancreatic cancer cells, GSK-3β activation confers a selective growth 
advantage to these cells, thus acting as a tumor promoter. Therefore, we 
investigated GSK-3β as a new druggable target and LiCl as new drug for 
cancer therapy. 
We demonstrated that LiCl was able to induce mesenchymal-epithelial 
reverting transition (MET) and cellular differentiation, affecting migration 
in our cell cultures.  
Spherical cancer models represent one of the major 3D in vitro models that 
have been described over the past 4 decades. These models have gained 
popularity in cancer stem cell research using tumorospheres. They 
contribute to chemoresistance, radioresistance, tumorigenicity, invasion and 
migration studies.  
We demonstrated that our cell cultures were able to aggregate to form 
spheroids in suspension and this capability was affected when cells were 
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incubated with LiCl. Furthermore, the inhibition of GSK-3β by LiCl, 
strongly down-regulated the expression of stem cell markers, such as Oct4, 
Sox2, Nanog, ALDH1 and LGR5, in cancer spheroids.  
Finally, we demonstrated that LiCl affected cellular plasticity, an important 
feature in tumor progression and metastasis; indeed, after LiCl treatment 
cancer cells were unable to switch from one phenotype to another. 
In conclusion, we set up an experimental system of primary mesenchymal 
colorectal cancer cell cultures to study the role of EMT in CRCs, and 
molecular basis of cell plasticity during cancer progression and acquisition 
of resistance to the therapy. Furthermore, we observed that LiCl induced 
MET and altered dynamic of cancer spheres formation, indicating 
differentiated state that correlates with expression of 
undifferentiation/differentiation markers, suggesting that GSK-3β and LiCl 
could represent an eligible target and a potential drug to set up therapy able 
to interfere with CRCs progression. 
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I- Molecular basis of colorectal cancer 
Colorectal cancer (CRC) is the third most frequent cancer worldwide and 
the fourth cause of cancer related deaths, implying a significant impact on 
public health especially in economically developed countries (Ferlay et al. 
2010, Ferlay et al. 2015, Karsa et al. 2010). 
During the development of colorectal adenocarcinoma, epithelial cells from 
gastrointestinal trait acquire mutations in specific oncogenes and/or tumor 
suppressor genes, conferring them a selective advantage on proliferation and 
self-renewal (Pancione et al. 2012, Ewing et al. 2014). Therefore, normal 
epithelium turns into a hyperproliferative mucosa and subsequently gives 
rise to a benign adenoma, which evolves into carcinoma and metastasizes in 
about 10 years. This model to explain CRCs progression is known as 
adenoma-carcinoma sequence (Volgestein et al. 1988). Sporadic CRCs, due 
to somatic mutations, account for about 70% of all CRCs. Familial CRCs, a 
group of diseases in which patients present a familial predisposition to 
develop cancer, are about 10-30%, whereas hereditary diseases are about 5-
7% (Burt 2000). 
The main hereditary CRC syndromes are hereditary nonpolyposis colorectal 
cancer (HNPCC) and adenomatous polyposis (FAP) syndrome (Rustgi 
2007). 
HNPCC, or Lynch syndrome, is an autosomal dominant disease which is 
caused by a germline mutation of DNA mismatch repair (MMR) genes, such 
as MLH1, MSH2, MSH6 and PMS2 (Aaltonen et al. 1998). 
FAP is a hereditary autosomal dominant syndrome associated with 
mutations of the tumor suppressor gene APC (adenomatous polyposis coli), 
which is located on chromosome 5q21-q22 (Groden et al. 1991, Kinzler et 
al. 1991). 
At molecular level, CRCs are a very heterogeneous group of diseases. 
Multiple genetic events are required for tumor progression, and genomic 
instability facilitates the acquisition of these mutations. Three mechanisms 
of genomic instability have been described in CRCs: Chromosomal 
instability (CIN), microsatellite instability (MSI) and aberrant DNA 
methylation (CpG island methylator phenotype- CIMP) (Goel et al. 2007, 
Boland and Goel 2010, Pino and Chung 2010) (Fig. 1). 
- CIN is observed in 85% of sporadic CRCs and involves in chromosomal 
translocations, rearrangements of parts of chromosomes and genes 
multiplications or deletions. CIN can lead to imbalances in chromosome 
number (aneuploidy) and loss of heterozygosity (LOH) (Pino and Chung 
2010). 
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-  MSI is detected in 15% of sporadic CRCs and in HNPCC patients; it is 
caused by alteration of the DNA mismatch repair mechanism. 
Microsatellites are repeated sequences of one to six DNA nucleotides units 
and MSI consequence is a variation in the number of these units (Horvat and 
Stabuc 2011). Based on instability degree, it is possible to distinguish two 
different MSI phenotypes: MSI high (MSI-H) and MSI low (MSI-L) (De la 
Chapelle and Hampel 2010). 
- CIMP is founded both in CIN and MSI CRCs, and is characterized by 
aberrant methylation of promoter CpG island sites, leading to alterations of 
several genes involved in tumor onset and progression (Lao and Grady 
2011). 
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II- Signaling pathways altered in CRCs 
It has been suggested a multistep model for the development of CRC, 
according to this model genetic and epigenetic mutations in oncogenes and 
tumor suppressor genes are required for the transition from benign adenoma 
to malignant carcinoma (Volgestein et al. 1988).  
Therefore, alterations of several pathways are involved in CRCs onset and 
progression, such as Wnt/APC/β-catenin, Ras/Raf, PI3K/AKT, NF-κB, 
TGF-β/Smad, p53 and mismatch repair (MMR) signaling (Fig. 1). 
These alterations confer individual susceptibility to cancer, and are 
responsible for responsiveness or resistance to antitumor agents (Colussi et 
al. 2013, Markowitz and Bertagnolli 2009). 
 
 
Figure 1. Molecular heterogeneity of CRCs. Several molecular mechanisms are involved 
in the onset and progression of CRCs. Several mutations in specific oncogenes and/or 
tumor suppressor genes are implicated into transition from adenoma to carcinoma. 
(Adapted from De Rosa et al. 2016). 
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Wnt/β-catenin pathway  
The key event in the onset of the majority of sporadic CRCs (about 70% of 
CIN CRCs) is the mutation of APC tumor suppressor gene, which is 
responsible also for FAP syndrome due to germline mutations (Colussi et 
al. 2013). 
APC protein plays an essential role in Wnt/β-catenin pathway. When Wnt 
ligand, a secreted glycoprotein, binds to its Frizzled (Fz) receptor, the 
multifunctional kinase GSK-3β is inactivated and β-catenin is stabilized and 
accumulates in the cytoplasm. Finally, β-catenin translocates into the 
nucleus where it interacts with members of the lymphoid enhancer factor 
(LEF)/T-cell factor (TCF) and activates specific target genes. In the absence 
of Wnt-signal, casein kinase 1 (CK1) and the APC/Axin/GSK-3β-complex 
phosphorylate β-catenin, targeting it for ubiquitination and proteasomal 
degradation (MacDonald et al. 2009). 
Wnt/β-catenin pathway is involved in many cellular processes 
(proliferation, differentiation, migration and stem cell self-renewal); indeed 
β-catenin regulates transcription of several genes such as Cyclin D1, CD44, 
c-myc oncogene and matrix metalloproteinase MMP-7 (Arber et al. 1996, 
Wielenga et al. 1999, He et al. 1998, Brabletz et al. 1999). 
 
Ras/Raf pathway 
Ras/Raf signaling is involved in mitogen-activated protein kinase (MAPK) 
activation, a group of serine/threonine kinase proteins which mediate signal 
transduction from plasma membrane to the nucleus in response to several 
extracellular stimulations, such as growth and mitogenic factors 
(Malumbres and Barbacid 2003, Scaltriti and Baselga 2006). Ras genes (H, 
K and N) encode for small proteins with GTPase activity bound to the 
plasma membrane. Ras mutations enhance GTP levels, leading to Raf 
proteins (A, B and C) phosphorylation and activation (Hallberg et al. 1994). 
Raf proteins transduce signals between MEK (1 and 2) and ERK (1 and 2) 
proteins, inducing transcription of genes involved in cell cycle and 
transcription regulation, such as c-myc and cyclin-D/CDK (Liebmann 2001, 
Shao et al. 2014). 
In CRCs, the early mutations are followed by events that promote cancer 
progression. It has been demonstrated that in 40% of CRCs the transition 
from adenoma to carcinoma is promoted by mutations of KRAS gene 
(Volgestein et al. 1988).  These mutations lead to a permanently active state 
of RAS pathway that permits cells to escape apoptosis and acquire a growth 
advantage (Malumbres and Barbacid 2003). 
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BRAF is frequently altered in several tumors and its mutations are mutually 
exclusive to KRAS mutations. In sporadic CRCs, BRAF has been found 
mutated in 10% of cases, specifically in MSI tumors (Parsons et al. 2012). 
In detail, the V600E mutation of BRAF gene represents a hotspot mutation, 
which lead to a constitutively active status of the Ras/RAF/MEK/ERK 
pathway (Di Nicolantonio et al. 2008). 
 
PI3K/AKT pathway 
The PI3K pathway is often dysfunctional in both sporadic and hereditary 
CRC; it activates cell growth, inhibits apoptosis and regulates cellular 
transformation, adhesion, motility and survival (Cantley 2002, Fruman et al. 
1998) in response to several extracellular signals, such as growth factors, 
cytokines, hormones, heat and oxidative stress, hypoxia, and hypoglycaemia 
(Testa and Bellacosa 2001, Martini et al. 2014, Vivanco and Sawyers 2002, 
Castellano and Downward 2011). 
Growth factor binds its receptor, and this event induces the activation of 
receptor by its self-phosphorylation. Consequently, PI3K is recruited at the 
plasma membrane and activated. The active form of PI3K converts 
phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3). PIP3 binds AKT anchoring it to the membrane 
and leading to its phosphorylation and activation via phosphoinositide-
dependent kinase-1 (PDK1) (Shaw and Cantley 2006, Fresno Vara et al. 
2004, Testa and Bellacosa 2001). AKT acts in many cellular processes 
(control of metabolism, translation, apoptosis and cell cycle) by 
phosphorylating several target proteins, such as BAD (BCL-2 antagonist of 
cell death), caspase-9, mTOR (mammalian target of rapamycin), GSK3β 
and β-catenin (Martini et al. 2014, Porta et al. 2014, Lee et al. 2010).  
PI3K/AKT pathway is negatively regulated by PTEN, which 
dephosphorylate PIP3 down-regulating its levels (Simpson and Parsons 
2001). Alterations of PTEN tumor suppressor gene are involved in several 
sporadic and hereditary CRCs. Somatic mutations in this gene, such as small 
quantitative alterations of its expression, have been founded to be associated 
to different types of cancer (Salmena et al. 2008). Furthermore, its germ-
line mutations cause PTEN hamartoma tumors (PHTS) syndrome, a 
hereditary disorder predisposing patients to onset of multiple neoplasms 
(Manfredi 2010, Eng 2003, Galatola et al. 2012). Recently it has been 
suggested that PTEN protein acts in a quantitative manner (Alimonti et al. 
2010), and quantitative changes in its expression levels could have a role in 
phenotypic variability shown by PHTS patients (Paparo et al. 2013). 
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NF-κB pathway 
NF-κB plays a key role in many physiological processes such as immune 
response, cell proliferation, cell death, and inflammation. NF-κB family is 
composed of five members: RelA (p65), RelB, cRel (Rel), NF-κB1 (p50 and 
its precursor p105) and NF-κB2 (p52 and its precursor p100), which are able 
to form homo- and heterodimeric complexes. The activity of these proteins 
is regulated by the IKK complex, consisting of two catalytic (IKKα and 
IKKβ) and one regulatory (IKKγ) subunits. In absence of signals, NF-κB 
dimers are sequestered in the cytoplasm by IκB proteins. Following 
stimulation by several signals, such as TNF-α (tumor necrosis factor- alpha) 
or IL-1 (interleukin- 1), IκB molecules are phosphorylated by the IκB kinase 
complex (IKK) leading to their ubiquitination and proteasomal degradation. 
IκB degradation releases NF-κB proteins in the cytoplasm, allowing them to 
translocate into the nucleus and activate transcription of specific target genes 
(Ghosh and Karin 2002). It has been demonstrated that NF-κB is 
constitutively activated in 60-80% of CRCs (Lind et al. 2001), and this 
promotes proliferation of cancer cells and rescues them from cell death 
(Hassanzadeh 2011).  
 
TGF-β/Smad pathway  
The TGF-β/Smad signaling pathway is involved in several biological 
processes, including cell proliferation, differentiation, migration and 
apoptosis. TGF-β binds to type II TGF-β receptors (TGFBR2), leading to 
recruitment and phosphorylation of the type I TGF-β receptor (TGFBR1) by 
TGFBR2. This event activates TGFBR1 protein kinase activity on two 
downstream transcription factors: SMAD2 and SMAD3. Phosphorylated 
SMAD2 and SMAD3 bind to SMAD4 and these SMAD complexes 
translocate into the nucleus to regulate the expression of specific target, such 
as genes involved in cell cycle checkpoint. Therefore, TGF-β induces cell 
cycle arrest and apoptosis, acting as tumor suppressor (Elliott and Blobe 
2005, Massague et al. 2000).  
TGFBR2 contains microsatellite sequences, which have been found altered 
in CRCs, especially in MSI tumors (Takayama et al. 2006, Grady et al. 
1999).  
Furthermore, it has been demonstrated that CIN CRCs are often 
characterized by the LOH of chromosome 18q, where Smad2, Smad4 and 
DCC genes are located and these mutations affect the response to TGF-β 
signalling (Lanza et al. 1998, Xu and Pasche 2007).  
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p53 pathway  
p53 is a tumor suppressor gene that regulates cell cycle arrest in response to 
DNA damage, inducing cell apoptosis. p53 protein acts by promoting 
transcription of target genes involved in cell cycle checkpoints. A major 
player in the p53 signaling is p21, which inhibits the formation of cyclin E-
cdk2 complexes responsible for cell cycle G1/S phase transition.  
p53 is also able to induce cell cycle arrest in G2 phase, by promoting the 
expression of proteins which retain CDC25C in cytoplasm. CDC25C is 
required for the activation of cyclin B-CDC2 complexes in the nucleus, 
which are essential for the G2/M phase transition (Harris and Levine 2005). 
Mutations of p53 have been found in about 50% of CRCs, furthermore p53 
is located on the short arm of chromosome 17 (17p), a region found deleted 
in more than 75% of CRCs. It has been demonstrated that these mutations 
are involved in CRCs progression and are late events, which lead to 
adenoma-carcinoma transition (Volgestein et al. 1988). 
 
MMR pathway 
MMR pathway corrects errors occurring during DNA replication and the 
main components of this system are MSH2, MSH3, MSH6, MLH1 and 
PMS2 proteins. MSH2 forms heterodimeric complexes with MSH6 or 
MSH3 proteins to recognize base mismatches or insertions/deletions, 
respectively; while MLH1 binds PMS2 and the resulting heterodimer 
manages the interaction between MSH2-MSH6/MSH3 complex and other 
factors required for repairs, such as DNA polymerases, helicases, 
exonucleases and single strand binding proteins (Kolodner and Marsishcky 
1999).  
Mutations of MMR proteins are characteristic of MSI CRCs, in particular 
epigenetic silencing of MLH1 gene has been often observed (Herman et al. 
1998). Defective MMR system lead to a 100-fold increase in the mutation 
rate in colorectal cancer cells, thus promoting tumor progression (Thomas 
et al. 1996). 
 
GSK-3β regulates cross talk between pathways involved in CRCs 
GSK-3β is a multifunctional serine/threonine kinase and an important 
regulator of cell survival that may act as anti- or pro-apoptotic factor, in a 
cell-specific manner. Its activity is regulated by site-specific 
phosphorylation. Full activity of GSK-3β generally requires 
phosphorylation at tyrosine 216 (tyr216), whereas phosphorylation at serine 
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9 (Ser9) inhibits its activity (Doble and Woodgett 2003, Jope and Johnson 
2004). 
More than 100 proteins are substrates of GSK-3β, among which β-catenin 
and NF-κB inhibitor IκB are the most well-known. The role of GSK-3β in 
cancer cells is controversial because this kinase is able both to interfere with 
cell proliferation, by inducing the degradation of β-catenin, and to contribute 
to cell survival by regulating NF-κB (Shakoori et al. 2005). 
In colon and pancreatic cancer cells, GSK-3β positively regulate NF-κB and 
its activation confers a selective growth advantage to tumor cells (Li et al. 
2014). 
A cross talk exists between NF-κB, Wnt and other adhesion proteins such 
as E-cadherin. E-cadherin directly binds to β-catenin and NF-κB at the 
plasma membrane level, subtracting them from the nucleus. NF-κB 
promotes the transcription of Wnt5A, which regulates several target genes 
including Snail. Snail down-regulates E-cadherin expression, leading to the 
release of β-catenin and NF-κB from the plasma membrane and making 
them available to translocate into the nucleus. GSK-3β mediates the cross 
regulation between Wnt and NF-κB Pathways (Du and Geller 2010). 
 
 
III- Epithelial-mesenchymal transition (EMT), cell plasticity and 
cancer progression 
EMT and its reverse process mesenchymal-epithelial transition (MET) are 
physiological mechanisms occurring during embryonic development and 
tissue remodelling. It has been suggested that EMT is also involved in cancer 
progression and metastasis in several tumors, including CRCs (Loboda et 
al. 2011).  
During EMT, epithelial cells lose epithelial features and acquire 
mesenchymal phenotype; these events are regulated by a group of 
transcription factors (EMT-TFs), including SNAIL, SLUG, ZEB1 and 
TWIST. The contribution of each EMT-TF is not homogeneous in all the 
cells, but it depends on cell type. Furthermore, the EMT-TFs influence each 
other and they can cooperate to regulate the expression of target genes (De 
Craene et al. 2013). 
A key event of EMT is the disruption of cell-cell junction characteristic of 
epithelial phenotype. To this aim, E-cadherin is cleaved and cannot interact 
with β-catenin to form adherens junctions; moreover, its expression is down-
regulated by the EMT-TFs (David and Rajasekaran 2012, De Craene 
and Berx 2013). 
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On the other hand, the EMT-TFs induce the expression of N-cadherin, 
normally localized at the membrane level of mesenchymal cells, conferring 
to the cells migratory properties. This “cadherin switching” is crucial in 
cancer cells, since they acquire the ability to detach from primary tumor and 
migrate into surrounding tissues (Wheelock et al. 2008). 
During EMT a cytoskeleton reorganization occurs. Specifically, the cell 
intermediate filament status changes from a keratin-rich network that takes 
part in adherens junctions and hemidesmosomes to a vimentin-rich network 
taking part in focal adhesions (Kokkinos et al. 2007). 
EMT programme can be induced by several signals, among which TGFβ 
signaling is the main pathway involved in the regulation of EMT. Other 
pathways able to induce EMT are Wnt, Notch, HGF, FGF, IGF1, EGF and 
VEGF; by promoting the expression of the EMT-TFs, manly SNAIL and 
TWIST (Lamouille et al. 2014). 
  
In the last few years, it has been demonstrated that a link exists between 
EMT and stemness. Indeed, EMT program induces the expression of stem 
cell genes, conferring to the cells the ability of self-renewal (Mani et al. 
2008). Thus, EMT in tumors can lead to generation of “cancer stem-like 
cells”, which have the capability to initiate new tumors (Reya et al. 2001). 
EMT could be a biological process common to several tumors, so it could 
represent a target mechanism to interfere with cancer progression.  
In CRCs, EMT has been observed at the invasive front producing single 
migratory cells, which could initiate the metastatic process. (Brabletz et al. 
2001). 
Metastases are the first cause of death in CRC, as well as in many other solid 
tumors. During metastases development, the cells detach from primary 
tumor and acquire the ability to invade the basal membrane, thus migrating 
into neighbouring tissues. Later, they interact with endothelial cells and 
enter in lymphatic and blood vessels, in a process known as intravasation. 
At last, the cells survived in the lumen of the vessels, come out from the 
vases (i.e. extravasation) and disseminate into the adjacent organs.  
Thus, EMT confers to the epithelial cancer cells all the features needed to 
complete this process, such as an increase of migratory and invasive ability 
and resistance to apoptosis (Thiery et al. 2009) (Fig. 2).  
The EMT-TFs are involved in the resistance to apoptosis of cells undergone 
EMT. It has been demonstrated that TWIST1 inhibits cell cycle arrest and 
apoptosis by impaired activation of p53 target genes (Vichalkovski et al. 
2010). Moreover, SNAIL is able to suppress TGF-β induced cell death, and 
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regulates components of the early to late G1 transition and the G1/S 
checkpoint, including the repression of Cyclin D2 transcription and the 
increase in p21 (Yang et al. 2006, Vega et al. 2004).  
The expression of N-Cadherin at the membrane level of cancer cells 
undergone EMT, facilitates their interaction with endothelial cells, which 
express not only VE-cadherin, but also N-cadherin, thus promoting 
intravasation (Wheelock et al. 2008). 
Once in a new distant site, MET program is induced, allowing cancer cells 
to grow, colonize the new tissue and generate metastases (Brabletz 2009) 
(Fig. 2). 
 
Figure 2. EMT and MET in metastasis development. Epithelial cancer cells undergone 
EMT acquire characteristics, which allow them to detach from tumor, entry and survive 
into lymphatic and blood vessels, come out from the vases and reach new tissues. EMT is 
reverted and MET allow cancer cells to grow and generate metastasis. (Adapted from 
Thiery 2002). 
 
 
It has been demonstrated that cellular plasticity plays a crucial role in tumor 
progression and metastasis. Indeed cancer cells that are able to switch from 
epithelial to mesenchymal phenotype and viceversa, show metastasis-
initiating potential; while disseminated cancer cells undergone EMT that 
lose the phenotypic plasticity are ineffective in seeding metastatic colonies. 
Several studies demonstrated that EMT and phenotypic plasticity are 
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associated with the acquisition of resistance to therapy (Chaffer et al. 2016, 
Doherty et al. 2016).  
 
IV- Cancer stem cell (CSCs) 
In the last decades, several authors proposed a new hierarchical model about 
how cancer growth is sustained. According to this hierarchy theory, tumors 
are heterogeneous and they are composed of several types of cells among 
which only a few are able to initiate the tumor. These cells show stem cell 
properties, such as self-renewal and multilineage differentiation capacity, 
and for this reason, they are called cancer stem cells (CSCs) (Vermeulen 
et al. 2008). 
The CSCs play a key role in cancer progression and metastases, and they are 
probably responsible for both relapse and resistance to therapy (Gangemi 
et al. 2009, Fanali et al. 2014). It is still unclear if CSCs derive from 
differentiated cancer cells, carriers of a somatic mutation, that can de-
differentiate, or alternatively they arise from healthy stem cells that 
accumulate genetic mutations and acquire a neoplastic phenotype (O’Brien 
et al. 2007, Greaves and Maley 2012). As mentioned above, EMT program 
induces the expression of stem cell specific markers, so cancer cells 
undergone EMT acquire both mesenchymal and stem cell-like phenotype. 
Therefore, EMT might be a source of CSCs or CSC-like cells (Reya et al. 
2001, Fan et al. 2012). 
CSCs derived from different tumors are characterized by the expression of 
specific surface markers; in particular, CD133 is one of the most used 
markers to isolate colorectal CSC. It has been demonstrated that 
CD133+ cells are able to generate a tumor, similar to the original lesion, 
when they are xenotransplanted in immunodeficient mice (O’Brien et al. 
2007). However CD133 expression has been found both in undifferentiated 
and differentiated cancer cells, suggesting that there is not an exclusive link 
between its expression and cancer cell stemness and tumorigenicity (Lugli 
et al. 2010).  
It has been suggested that other markers, such as CD44, CD166, EpCAM, 
CD24, CD29, LGR5 and ALDH1, have a role in stemness, invasiveness and 
metastasis in colorectal cancer (Vermeulen et al. 2008, Lugli et al. 2010). 
CD44 gene is composed of 19 exons and it encodes for different isoforms, 
generated by alternative splicing of exons 6-14 (also known as v2-v10). All 
these proteins have the same N- and C-terminus domain. The N-terminus 
domain (encoded by exons 1-5) interacts with hyaluronic acid, while the C-
terminus (encoded by exons 15-19) is a trans-membrane domain that sticks 
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out into cytoplasm. Depending on which exons are included in the final 
transcript, the isoforms differ for the extracellular membrane proximal insert 
(Gotley et al. 1996). 
CD44 overexpression is associated with CRCs progression, and in detail, it 
has been proposed that the CD44v6 isoform is involved in the migration of 
colorectal CSCs and generation of metastases (Du et al. 2008, Todaro et al. 
2010).  
Aldehyde dehydrogenase (ALDH) protein is involved in alcohol 
metabolism, and its overexpression is correlated to CRCs aggressiveness 
and metastases (Hou et al. 2013). Moreover, it has been demonstrated that 
ALDHhigh cancer cells show stem cell properties and elevated tumorigenic 
potential (Shenoy et al. 2012). 
The leucine-rich-repeat-containing G-protein coupled receptor 5 (LGR5) 
gene encodes the R-spondin receptor, which is an agonist of the canonical 
Wnt pathway. LGR5 is expressed in stem cells at the crypt base of intestinal 
epithelium and it has been suggested that LGR5-positive cancer cells might 
become CSCs in tumors (Barker et al. 2007). 
 
Given the role of CSCs in cancer metastasis and drug resistance, it becomes 
relevant to study their molecular biology to develop therapies able to target 
these cells. 
CSCs can be isolated from cancer cell cultures and propagated in vitro to 
test their ability of self-renewal. As mentioned above, one of the main 
feature of CSCs is the ability to differentiate leading to the generation of the 
different lineages of cancer cells, which constitute the whole tumor. In vivo 
experiments are necessary to test tumorogenicity of CSCs, through 
transplantations in immunodeficient non-obese diabetic (NOD)/severe 
combined immunodeficient (SCID) mice (Tirino et al. 2012). 
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Metastases are the main cause of death in patients affected by CRCs, thus 
the understanding of the molecular basis of this mechanism is useful to set 
up therapies and interfere with cancer progression. Recently, it has been 
suggested that EMT, which is a physiological process, is borrowed by cancer 
cells to carry out invasion and metastases. EMT program is orchestrated by 
a group of transcription factors (EMT-TFs), including SNAIL, SLUG, 
ZEB1 and TWIST. During EMT, the cells lose the expression of E-
Cadherin, that guarantees the epithelial phenotype, and acquire 
mesenchymal characteristics.  
EMT program provides to the epithelial cells all the traits that are needed to 
drive on metastases development such as an increase of migratory and 
invasive properties, resistance to apoptosis and stem cell-like features 
allowing cancer cells to generate a new tumor in a distant site. Moreover, 
several studies suggest that EMT is involved in the acquisition of 
pharmacological resistance by cancer cells.  
Cellular plasticity is the ability to switch from one phenotype to another, and 
it is a crucial feature of cancer cells in metastasis development. 
Genomic instability facilitates the accumulation of multiple mutations 
during the development of CRC, chromosomal instability (CIN) is observed 
in 85% while microsatellite (MSI) is detected in 15% of sporadic CRCs. 
Molecular mechanisms underlying CRC progression is still poorly 
understood, especially for MSI CRCs.  
GSK-3β is a key regulator of the cross talk between different signaling 
pathways involved in CRCs development. GSK-3β is a multifunctional 
serine/threonine kinase and an important regulator of cell survival that may 
act as anti- or pro-apoptotic factor, in a cell-specific manner. In colon and 
pancreatic cancer cells, GSK3β acts as oncogene since it positively regulates 
NF-κB and its activation confers a selective growth advantage to tumor 
cells.  
Given all these data, we decided to investigate genes and mechanisms 
responsible for EMT and stemness in CIN and MSI CRCs, with the main 
purpose to shed light on metastases development and mechanisms for cancer 
relapses and resistance, thus identifying new targets for cancer therapy and 
new prognostic and predictive biomarkers. 
We also elucidate the role of GSK-3β and LiCl (its specific inhibitor) as 
eligible target and a potential drug to develop therapy able to affect CRCs 
progression and metastases, respectively. 
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To realize these main objectives we fulfil the following aims: 
 
a) Biological samples collection from CRC patients 
We sampled pairs of normal colorectal mucosa and its matched colorectal 
cancer tissues from patients with sporadic and hereditary colorectal cancer 
and frozen them in liquid nitrogen. We also collected peripheral blood, 
sampling DNA, RNA, proteins and serum. Primary cell cultures were 
established from healthy mucosa and cancer tissues as previously described 
(Costabile et al. 2015).  
 
b) Genetic characterization of primary colorectal cancer cell cultures 
To achieve this objective, primary colorectal cancer cell cultures were 
analysed for MSI and CIN status, and cancer cells were assessed for co-
expression of epithelial and mesenchymal markers, by using 
immunofluorescence assay (Costabile et al. 2015).  
 
c) Investigation of genes and mechanisms involved in the EMT and 
stemness of CIN and MSI CRCs 
To this aim, two mesenchymal primary colorectal cancer cell cultures, 
established from CIN and MSI CRCs, were grown as spheres in serum-free 
stem cell medium. Indeed, it is reported that only stem cells and/or stem-like 
cells, but not differentiated cancer cells, are able to survive and grow in these 
conditions. 
Both cell cultures, adherent cancer cells and spheroids, were analysed for 
expression of the main EMT-TFs, such as Twist1 and Snail, and other EMT 
specific proteins, such as E-cadherin, N-cadherin and Vimentin, by using 
immunofluorescence assay, Western Blot and Real Time RT-PCR. We also 
evaluated the expression of the main stem cell biomarkers, such as LGR5, 
ALDH1, Oct-4, Sox-2 and Nanog.  
 
d) Investigation of the effect of GSK-3β inhibition on EMT  
To shed light on the role of GSK-3β in EMT and CRC progression, we 
evaluated effects of LiCl incubation on the expression of mesenchymal and 
stemness biomarkers both in adherent cancer cells and spheroids. We also 
assessed cell response to GSK-3β inhibition on cell migration and plasticity, 
by using wound healing assay and hanging drop assay.  
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2.1 Patients  
Blood samples, normal colorectal mucosa and colorectal cancer tissues have 
been obtained from patients with sporadic colon cancer operated in the 
“Istituto Nazionale Dei Tumori- Pascale” in Naples (Italy). Tissues have 
been frozen in liquid nitrogen to realize a bio-bank.  
Samples from all patients have been collected after authorization from the 
“Comitato Etico per le Attività Biomediche- Carlo Romano” of the 
University of Naples Federico Ⅱ, with protocol no. 120/10. This 
authorization has been obtained once the study received ethics approval, the 
participants have been informed and written consent has been signed. 
 
2.2 Cell cultures 
Samples of colorectal cancer have been washed overnight at 4˚C in PBS 
containing 300 U/ml penicillin, 300 µg/ml streptomycin and 2.5 µg/ml 
amphotericin B (all from Gibco BRL- Karlsruhe, Germany). Then they have 
been finely minced with scissors and incubated in 2 ml 0.1% collagenase II 
(Boehringer Mannheim- Mannheim, Germany) for 1 h at 37˚C and 5% CO2. 
Cell suspension has been collected by centrifugation, washed twice with 
PBS, and subsequently cultured in DMEM/F12 (1:1) containing 10% FBS 
medium, 100 U/ml penicillin, 100 µg/ml streptomycin and 2.5 µg/ml 
amphotericin B.  
Colorectal cancer cells have been selected by differential sedimentation. 
To inhibit GSK-3β activity, cells have been incubated in the same medium 
containing 30 mM LiCl for 1h, 24h and 10 days.  
To evaluate cell migration, we performed wound-healing assay as described 
by Rodriguez et al. (Methods Mol Biol, 2005). 
 
2.3 Hanging drop assay 
Cells have been diluted at a final concentration of 3.7x104 cells/ml in 
DMEM/F12 (1:1) containing 2% FBS medium, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2.5 µg/ml amphotericin B, 10µg/ml bFGF and 20 
µg/ml EGF. 27µl drops have been seeded on the cover of the plate and 
incubated at 37˚C and 5% CO2 for 72h. In these conditions, cells aggregate 
to form 3D spheroids. 
 
2.4 Cytogenetic analysis 
Cytogenetic analysis has been performed by the cytogenetic service of the 
Department of Molecular Medicine and Medical Biotechnologies of 
University of Naples, Federico II. 
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Metaphase chromosome analysis has been performed on cell cultures from 
colorectal cancer tissues, by using high-resolution G-banding (550 bands) 
according to standard procedures. Multicolor-FISH (M-FISH) has been 
carried out using MetaSystems' 24Xcyte color kit (MetaSystems GmbH). 
FISH analysis has been performed using whole chromosome painting 
(WCP) probes for chromosomes 20 and 22 and locus specific DiGeorge 
probe mixture (MetaSystems GmbH) containing a Spectrumorange probe 
located at 22q11.2, a Spectrumgreen LSI probe mapping the 22q13.3 region 
and subtelomeric probes for the p (green) and q (red) arms of chromosomes 
20. Multicolor chromosome banding (MCB) has been performed using the 
multicolor banding DNA probe kit based on microdissection derived region 
specific libraries for chromosome 22 (MetaSystems GmbH) according to 
standard protocols (Liehr et al. 2002). 
FISH experiments have been performed on metaphase spreads and 
fluorescent images have been analysed using a fluorescence microscope 
(Axio Imager.Z1 mot; Carl Zeiss Microscopy, LLC) with ISIS software 
imaging system (MetaSystems gmbh) for image capturing and processing. 
 
2.5 RER assay 
The MSI status has been confirmed with a fluorescent multiplex system 
including six mononucleotide repeats (BAT-25, BAT-26, BAT-40, NR21, 
NR24, and TGFΒRⅡ) and four dinucleotide repeats (D2S123, D5S346, 
D17S250, and D18S58) as described earlier (Duraturo  et al. 2013), using 
the CC-MSI kit (AB Analitica s.r.l), according to the manufacturer's 
instructions. PCR products have been analysed by capillary electrophoresis 
analysis using an ABI Prism 3130 Genetic Analyzer (Applied Biosystems). 
 
2.6 RT-PCR analysis 
Total RNA has been extracted from primary colorectal cancer cells and 
tissues of CRC patients, after homogenization, using Qiazol reagent 
(Qiagen) according to the manufacturer's instructions. 1µg of total RNA has 
been treated with DNAse (Invitrogen Life Technologies) and cDNA has 
been synthesized by mixing 500ng random hexamers, 1mM dNTPs, 1µl 
SuperScriptIII Reverse Transcriptase, 4µl 5X RT buffer, 1µl DTT 0.1M and 
nuclease-free water to 20µl (Invitrogen Life Technologies).  
The reaction has been run in a thermocycler for 60 min at 55˚C, heated to 
70˚C for 15 min and quickly chilled on ice. 1µl cDNA has been amplified 
by RT-PCR using CTK20, CTK18 and E-cadherin primer pairs (Table 2.1). 
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All oligonucleotides have been obtained by using Primer-BLAST Software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
Table 2.1 Oligonucleotide sequences 
 
2.7 Real-time PCR quantification analysis 
Real-time PCR quantification analysis has been performed on 0.5µl cDNA, 
using Twist1, Snail, Vimentin and Cyclooxygenase-2 (COX2) primer pairs 
(Table I). Relative expression has been calculated with the comparative Ct 
method and normalized against the Ct of glucuronidase (GUS) mRNA. 
Quantitative Real-time assay has been performed by using the Bio-Rad 
iCycler iQ Real-Time PCR Detection System (Bio-Rad laboratories) as 
previously described (Galatola et al. 2012, Galatola et al.  2013). 
Healthy mucosa (HM) has been used as a control to measure the relative 
expression in colorectal cancer cells and tumor tissue of the same patient. 
All statistical analyses have been computed using Prism software. The 
unpaired two-tailed t test with confident intervals of 99% was calculated. A 
value of p <0.005 was considered statistically significant. 
 
 
 
Gene                         Primers Accession no. 
CTK 18 F:5'-AGACTGGAGCCATTACTTC-3' 
R:5'-GCTCTGTCTCATACTTGACTC-3' 
[NM_199187.1; start +441] 
[NM_199187.1; start +563] 
CTK 20 F:5'-CTGCAAATTGATAATGCTAA-3' 
R:5'-GGTCATCAAAGACCTTATTC-3' 
[XM_005277792.1; start +485] 
[XM_005277792.1; start +586] 
E-Cad F:5'-TCCTGGGCAGAGTGAATTTT-3'   
R:5'-CCGTAGAGGCCTTTGACTG-3' 
[NM_004360.3; start +276] 
[NM_004360.3; start +381] 
Snail 1 F:5'-GCGAGCTGCAGGACTCTAAT-3' 
R:5'-TCCCAGATGAGCATTGGCAG-3' 
[NM_005985.3; start +143] 
[NM_005985.3; start +269] 
Twist1 F:5'-CCTTCTCGGTCTGGAGGAT-3' 
R:5'-TCCTTCTCTGGAAACAATGACA-
3' 
[NM_000474; start +908] 
[NM_000474; start +1004] 
Vim 
 
F:5 '-TCTGGATTCACTCCCTCTGG-3' 
R:5'-GGTCATCGTGATGCTGAGAA-3' 
[NM_003380; start +1694] 
[NM_003380; start +178] 
COX2 F: 5’-CAGCACTTCACGCATCAGTT -3’ 
R:5’-CGCTGTCTAGCCAGAGTTTCA -
3’ 
[NM_000963.3; start 702] 
[NM_000963.3; start +820] 
GUS F:5'-GAAAATATGTGGTTGGAGAGC-3' 
R: 5'-CCGAGTGAAGATCCCCTTTTT-3' 
[XR_242233.2; start +1695] 
[XR_242233.2; start +1774] 
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2.8 Western blot assay 
Total proteins have been extracted from colorectal healthy mucosa (HM) 
and tumor tissue (TT) of patients, and from primary colon cancer cultures, 
using Qiazol reagent (Qiagen) following the manufacturer's instructions. 
Proteins concentration has been determined by using Bradford assay (Bio-
Rad laboratories), adopting bovine serum albumin standards. 30µg of 
proteins have been separated by SDS-polyacrylamide gel electrophoresis 
and blots have been prepared on an Amersham Hybond-ECL nitrocellulose 
membrane (Amersham Pharmacia Biotech). Primary antibody against β-
catenin (rabbit polyclonal anti-human; no.9581), E-cadherin (rabbit 
monoclonal anti-human; no.3195), CD44 (mouse monoclonal anti-human; 
no.5640), Snail (rabbit monoclonal anti-human; no.3879) and Vimentin 
(rabbit monoclonal anti-human; no.5741) have been from Cell Signalling 
technology. Primary antibody against Actin (polyclonal, rabbit anti-human; 
sc-1615) has been from Santa Cruz Biotechnology, Inc. The membrane has 
been probed with a secondary antibody against peroxidase-conjugated rabbit 
or mouse immunoglobulin g, and immunoreactivity has been detected using 
the enhanced chemiluminescence Immobilon Western HRP Substrate 
(Millipore). 
 
2.9 Immunofluorescence 
Primary colorectal cancer cells have been seeded and grown in 12-well 
cultivation chambers (ibidi). After fixation in 4% paraformaldehyde (PFA)-
PBS for 10 min, cells have been permeabilized in 0.1% Triton X-100-PBS 
and then have been blocked in 10% FBS- 0.1% Triton X-100-PBS for 45 
min. Cells have been incubated overnight with primary antibodies (Table 
2.2) and with secondary antibodies (Alexa Fluor 546 donkey anti-rabbit 
A10040, Alexa Fluor 488 donkey anti-mouse A21202; Thermo Fisher) for 
1h and with DAPI (SIGMA-Aldrich) for 30min to label nuclei. Negative 
controls without primary antibodies have been also included and no staining 
has been observed. Immunofluorescence has been visualized under a 
fluorescence confocal microscope Zeiss LSM 700 and image have been 
captured.  
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Table 2.2 Primary Antibodies used for immunofluorescence analysis. 
Antibodies 
Pan-cytokeratin (no.74384347, Thermo Fisher) E-cadherin (no.76055, Abcam) 
Nanog (no.3580, CST) N-cadherin (no.76057, Abcam) 
Sox2 1:50 (no.4900, CST) Snail (no.180714, Abcam) 
Oct4 (no.2840, CST) LGR5 (no.135238, Santa Cruz) 
Vimentin (no. 5741, CST) ALDH1 (no.24343, Abcam ) 
CD44 (no.5640, CST) β-catenin (no.9581, CST) 
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3.1 Isolation and molecular characterization of primary colorectal 
cancer cell cultures 
We realized a tissue biobank by sampling pairs of healthy colorectal mucosa 
and its matched tumor tissues, freezing them in liquid nitrogen. From the 
same tumor tissues, we established primary colorectal cancer cell cultures. 
We decided to analyze two of these cell cultures, T88 and T93, isolated from 
tumor tissue of patient number 88 and patient number 93 of our bio-bank. 
The classification of these two tumors was T3N1 and T4N2, according to 
TNM staging. These cells were characterized by different morphologies, 
specifically T88 were elongated and resembled the mesenchymal 
phenotype, while T93 showed a cuboidal shape that is more characteristic 
of epithelial cells (Fig. 3.1). 
 
Figure 3.1. T88 and T93 cell cultures. Images in a bright field with x20 magnification 
(Scale bar 50µm).  
 
To prove the cancer status of these cell cultures, we performed cytogenetic 
analysis. T93 cells showed a female karyotype with a reciprocal 
translocation between the q arm of chromosome 20 and the q arm of 
chromosome 22 in 95% of analysed karyotypes; no numerical aberrations 
were found (Fig. 3.2A). The high resolution MCB image of the normal 
chromosome 22 compared to the rearranged chromosome 22 showed that 
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the 22q13.2qter region of chromosome 22 was translocated to chromosome 
20, while the translocated region of chromosome 20 includes the region 
20q13 to 20qter (Fig. 3.2B). FISH analysis was performed by using 
subtelomeric probes for the p (green) and q (red) arms of chromosomes 20 
to confirm the presence of this rearrangement (Fig. 3.2C). The complete 
chromosomal characterisation according to ISCN 2013 (Shaffer et al. 
2013)was: 46,XX,t(20;22)(q13;q13)(20pter→20q13.2::22q13.2→22qter: 
22pter→22q13.::20q13→20qter). 
 
Figure 3.2. Cytogenetic analysis of T93 cell culture. (A) multicolor-FISH (M-FISH) showed 
a reciprocal translocation between chromosomes 20 and 22; (B) high resolution multicolor 
chromosome banding (MCB) image of the normal chromosome 22 compared to the 
rearranged chromosome 22; (C) FISH with subtelomeric probes for the p (green) and q 
(red) arms of chromosome 20. 
 
Since patient 88 did not show chromosomal alterations, we tested his DNA 
for microsatellite instability. Thus, we performed MSI assay on DNA 
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extracted from his tumor tissue and peripheral blood sample, founding MSI-
high (MSI-H) status, with instability at mononucleotide markers NR21, 
BAT40 and NR24 (Fig. 3.3).  
 
Figure 3.3. Microsatellite instability assay of patient 88. We performed this analysis on 
DNA   extracted from (A) peripheral blood cells and (B) tumor tissue. Black arrows 
indicate altered microsatellites. 
 
3.2 T88 and T93 cell cultures express EMT-TFs, mesenchymal, 
epithelial and stemness markers 
We analysed the expression of several markers in T88 and T93 cells, by 
performing RT-PCR, Real-Time RT-PCR, Western Blot and 
immunofluorescence assay.  
COX2 and EMT-TFs (Twist and Snail) messengers were upregulated in 
both cell cultures compared to tumor tissue (TT) and healthy mucosa (HM) 
of each patient, when investigated by Real-Time RT-PCR (Fig. 3.4 A and 
B). For relative quantification, each HM was adopted as control sample. 
Western Blot results showed that protein expression of the epithelial marker 
E-cadherin was down-regulated in patient 88 and upregulated in patient 93 
TTs compared to matched HMs, while it gave no hybridization signal in 
Results 
 
 56 
primary tumor cell cultures, in this Western Blot assay and in our 
experimental conditions. On the contrary, the mesenchymal protein 
Vimentin and the EMT-TF Snail were upregulated in TTs, when compared 
to HMs, and resulted highly expressed in tumor cell cultures. Finally, CD44 
was upregulated in both cell cultures and in TT from patient 88 but it gave 
no signal in TT and HM from patient 93, in our experimental conditions 
(Fig. 3.4 C and D). Then we performed RT-PCR to analyse the expression 
of Cytokeratin 18 and 20, normally expressed in epithelial cells. As it is 
shown in Figure 3.4 E and F, HMs and TTs expressed both Cytokeratins, 
while T88 and T93 tumor cells expressed only Cytokeratin 18, according to 
its specific expression in colorectal cancer cells. 
 
 
 
 
Figure 3.4. Expression analysis of several markers in T88 and T93 cell cultures. (A- B) 
Real-time RT- PCR analysis of Twist1, Snail and cyclooxygenase-2 (COX2), performed on 
healthy mucosa (HM), tumor tissue (TT) and untreated tumor cell cultures (T) from patient 
(A) 88 and (B) 93. (C- D) Western Blot assay of E- cadherin, CD44, Vimentin, Snail and 
Actin performed with 30μg of proteins extracted from HM, TT and untreated T from patient 
(C) 88 and (D) 93. (E-F) RT- PCR analysis of cytokeratin 20 (E) and 18 (F) performed on 
cDNA from HM, TT and untreated T from patient 88 and 93. 
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To understand if T88 and T93 cell cultures were heterogeneous cell 
populations or all cells expressed both epithelial and mesenchymal markers, 
together with high level EMT-TFs and stemness biomarkers, we performed 
immunofluorescence assay. As shown in Figure 3.5, we evaluated the 
expression of epithelial and mesenchymal biomarkers, such as Vimentin, 
pan-Cytokeratin, E- and N-Cadherin, the expression of the EMT-TF Snail, 
and the expression of CD44 and β-catenin, proteins playing a pivotal role in 
CRC development and progression (Fig. 3.5 A, B, C and D). We also 
analysed the expression of several stem cells specific markers such as 
Nanog, Oct4, Sox2, ALDH1 and LGR5. All the cells of both cultures 
expressed all these tested markers (Fig. 3.5 D, E and F).  
Results 
 
 58 
  
Figure 3.5. T88 and T93 cell cultures expressed epithelial, mesenchymal and stemness 
markers. Confocal microscopy images of immunofluorescence analysis on T88 and T93 
cells performed with (A) Vimentin/ pan-Cytokeratin, (B) N-/ E-Cadherin, (C) β-Catenin/ 
CD44, (D) Snail/ LGR5, (E) Nanog/ALDH1 and (F) Oct4/ Sox2 antibodies. 
 
As shown in Figure 3.5 A, Vimentin and Cytokeratin co-localized at 
cytoskeleton level in all analysed cells, while CD44 was predominantly 
expressed at plasma membrane level (Fig. 3.5 C). As expected, β-Catenin 
localized into the nucleus and at cytoplasm and plasma membrane level (Fig. 
3.5 C). We also observed that T88 and T93 cells expressed both E- and N- 
Cadherin proteins. E-cadherin, which did not give a signal when analysed 
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by Western Blot assay, as previously reported (Fig. 3.4C and D), showed a 
low immunofluorescence hybridization signal, while interestingly, N-
cadherin showed an unexpected nuclear localization (Fig. 3.5B). As 
expected, Snail and LGR5 localized mainly into the nucleus but they were 
also expressed at the cytoplasm level (Fig. 3.5D). Concerning about the 
analysed stem cell biomarkers, both T88 and T93 cell cultures expressed 
ALDH1, Nanog, Oct4 and Sox2; however, Nanog was more expressed into 
the nuclei of T88 cells, and Oct4 and Sox2 into the nuclei of T93 cells (Fig. 
3.5F and G). 
 
3.3 GSK-3β inhibition, by Lithium Chloride, induces Mesenchymal to 
Epithelial transition in T88 and T93 cell cultures 
We studied the role of GSK-3β protein during the EMT of CRC cells, by 
incubating T88 and T93 cells with Lithium Chloride (LiCl), a specific GSK-
3β inhibitor. After 10 days of treatment, cells changed their morphology and 
differentiated (Fig. 3.6). 
 
Figure 3.6. LiCl induced differentiation of T88 and T93 cell cultures. Images in bright field 
of T88 and T93 before treatment (A-C) and after 10 days of incubation with Lithium 
Chloride (B-D). Magnification x20 (Scale bar 50µm).  
 
After LiCl treatment, we analysed the expression of EMT-TFs and of 
epithelial and mesenchymal markers, in T88 and T93 cells (Fig.3.7).  
We observed that Twist1, Snail, COX2 and CD44 expression was down-
regulated (Fig. 3.7A, B, C and D) and cells, originally negative for E-
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cadherin, started to express this epithelial marker both at RNA (Fig. 3.7G 
and H) and protein level (Fig. 3.7C and D), suggesting a mesenchymal-to-
epithelial reverting transition process. According to the previously described 
observation (Fig. 3.1), T88 untreated cells were more mesenchymal-like 
than the T93 cells, and did not express E-cadherin.  
On the other hand, T93 untreated cells that showed more epithelial-like 
morphology, had low level of E-cadherin transcription (Fig. 3.7G and H). 
When analysed by western blot assay, Snail and CD44 gave no signal after 
10 days of LiCl incubation in T93 cells, while they strongly decreased in 
T88 cells (Fig. 3.7C and D). Interestingly, β-catenin and vimentin showed 
an opposite trend in response to GSK3β inhibition (Fig. 3.7C and D). 
After 10 days of LiCl incubation, expression of Vimentin mRNA and 
protein strongly decreased in T93 cells (Fig. 3.7F and D) while they 
increased in T88 cells (Fig. 3.7E and C). On the other hand, in the same 
conditions, β-catenin was up-regulated in T93 cells and down-regulated in 
T88 cells (Fig. 3.7C and D).  
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Figure 3.7. Effects of LiCl incubation on T88 and T93 cells. (A-B) Real-time RT- PCR 
analysis of Twist1, Snail and COX2 performed on HM, TT, untreated cells (T), and tumor 
cells after 1h, 24h and 10 days of LiCl incubation from patient (A) 88 and (B) 93. (C -D) 
Western blot assay of E- cadherin, β-Catenin, CD44, Vimentin, Snail and Actin performed 
on proteins extracted from untreated cells (T) and cells after 1h, 24h and 10 days of LiCl 
incubation of (C) T88 and (D) T93 cell cultures. (E-F) Real-time RT- PCR analysis of 
Vimentin performed on HM, TT, untreated T, and tumor cells after 1h, 24h and 10 days of 
LiCl incubation from patient (E) 88 and (F) 93. (G-H) RT- PCR analysis of E- cadherin 
performed on cDNA from HM, TT and untreated T from patient (G) 88 and (H) 93. 
 
To confirm these observations and to investigate protein localization after 
GSK-3β inhibition, we performed immunofluorescence assay of cells 
incubated with LiCl (Figure 3.8) 
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Figure 3.8. Expression of epithelial, mesenchymal and stemness markers in T88 and T93 
cell cultures after 10 days of treatment with LiCl. Confocal microscopy images of 
immunofluorescence analysis on T88 and T93 cells performed with (A) Vimentin/ pan-
Cytokeratin, (B) N-/ E-Cadherin, (C) β-Catenin/ CD44, (D) Snail/ LGR5, (E) 
Nanog/ALDH1 and (F) Oct4/ Sox2 antibodies. 
 
As shown in Figure 3.8A, Vimentin and Cytokeratin co-localized as in 
untreated cells, however it was manifest a different cytoskeleton 
organization after treatment with LiCl. E-Cadherin was more expressed than 
in untreated cells, according to Western Blot and RT-PCR results, while N-
Cadherin was down-regulated and its nuclear localization was lower than 
that observed in untreated cells (Fig. 3.8B). After 10 days of incubation with 
LiCl, CD44 expression was reduced, according to results obtained by 
Western Blot assay, and β-catenin was mainly localized at membrane level 
and less into the nuclei of these cells respect to the untreated cells (Fig. 
3.8C). We also observed that the expression at nuclear level of the EMT-TF 
Snail (Fig. 3.8D), as well as all stemness markers analysed (LGR5, ALDH1, 
Nanog, Oct4 and Sox2) was down-regulated (Fig. 3.8D, E and F). 
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3.4 GSK-3β inhibition reduces migration in T88 and T93 cell cultures  
Once analysed the effect of GSK-3β inhibition at molecular level, we 
decided to investigate cell migration capability in response to LiCl 
treatment. To this aim, we performed a wound healing assay on T88 and 
T93 cell cultures. After 24h, untreated cells of both cultures began to migrate 
and the wound was completely healed after 72h (Fig. 3.9A and C). On the 
contrary, T88 and T93 cells treated with LiCl were completely unable to 
migrate (Fig. 3.9B and D). 
 
Figure 3.9. Wound healing assay on T88 and T93 cells. The wound healing was performed 
on (A-C) T88 and T93 untreated cells and on the same cells incubated with 30 mM Lithium 
Chloride. Image in bright field x4 magnification (Scale bar 250μm). 
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3.5 Isolation and molecular characterization of colorectal cancer stem-
like cells from T88 and T93 cell cultures 
T88 and T93 cells underwent EMT and they expressed not only epithelial 
and mesenchymal markers but also stemness markers, and this is in 
accordance with literature data reporting that EMT confers to the cells stem 
cell-like properties (Mani et al. 2008).  
Primary mesenchymal colon cancer cells were cultured as spheres in low 
adhesion plates and serum-free medium. It is indeed reported that only stem 
cells and/or stem cell-like cells are able to survive and grow in these 
conditions (data not shown).  
Cells were also placed in hanging drop culture and incubated under 
physiological conditions, in low serum concentration medium, until they 
form 3D spheroids (Fig. 3.10).  
As show in Figure 3.10, after 24 hours, T88 and T93 cells aggregated to 
form spheroids in suspension 
 
 
Figure 3.10. T88 and T93 cells were able to grow as spheres. Hanging drop assay 
performed on (A-B) T88 and (C-D) T93 cell cultures. Images in bright field with (A-C) x4 
and (B-D) x20 magnification (Scale bar 250µm and 50µm). 
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Thus, we performed confocal immunofluorescence assay on cancer 
spheroids of the same epithelial, mesenchymal and stemness markers 
previously analysed on adherent cells (Fig. 3.11). First, we analysed cancer 
spheroids grown in suspension for six passages, passing cells every 10 days 
(data not shown). Later we analysed spheroids obtained in hanging drop 
assay, as previously described, and the results were quite similar.  
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Figure 3.11. T88 and T93 cancer spheroids expressed epithelial, mesenchymal and 
stemness markers. Confocal microscopy images of immunofluorescence analysis on T88 
and T93  cells performed with (A) Vimentin/ pan-Cytokeratin, (B) N-/ E-Cadherin, (C) β-
Catenin/ CD44, (D) Snail/ LGR5, (E) Nanog/ALDH1 and (F) Oct4/ Sox2 and antibodies. 
 
As shown in Figure 3.11, T88 and T93 cancer spheroids stored expression 
of the epithelial Cytokeratins and E-Cadherin, and mesenchymal Vimentin 
and N-Cadherin, markers; however, N-Cadherin did not show a high nuclear 
localization, as in T88 and T93 cells growth in adhesion (Fig. 3.11A and B). 
CD44 was mainly expressed at membrane level, like β-Catenin (Fig. 3.11C). 
Furthermore, cells in cancer spheroids showed a lower nuclear expression 
of the EMT-TF Snail, respect to original T88 and T93 cell cultures (Fig. 
3.11D); the stemness markers Nanog, Oct4, Sox2, LGR5 and ALDH1 were 
expressed and they showed a turnover between nucleus and cytoplasm. 
Nevertheless, the expression of Oct4 was very low in T93 cancer spheroids, 
while T88 spheroids showed very low level of ALDH1 expression (Fig. 
3.11E and F).  
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3.6 Inhibition of GSK-3β by LiCl affects stem cell-like properties of T88 
and T93 cancer spheroids and alters cell plasticity 
Since inhibition of GSK-3β reverted EMT program in T88 and T93 adherent 
cell cultures, we also evaluated the effect of LiCl on cells ability to grow as 
cancer spheres in serum-free medium.  
Thus, we performed hanging drop assay adding this drug to the cell culture 
medium. As showed in Figure 3.12, after 72 hours of LiCl incubation, T88 
cells formed 3D structures that lost the spherical shape, while T93 cells 
completely lost their ability of sphere formation generating only cellular 
aggregates. 
 
Figure 3.12. T88 and T93 cells ability to form spheroids was affected by LiCl. Hanging 
drop assay performed on (A-B) T88 and (C-D) T93 cell cultures treated with 30mM LiCl 
for 72 hours. Images in bright field with (A-C) x4 and (B-D) x20 magnification (Scale bar 
250µm and 50µm). 
 
To clarify the molecular basis of the GSK-3β inhibition on the ability of T88 
and T93 cells to grow as spheres, we performed immunofluorescence assay 
of epithelial, mesenchymal and stemness markers in cancer spheroids 
obtained in hanging drop assay from cells treated with LiCl (Fig. 3.13). 
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Figure 3.13. LiCl effect on the expression of epithelial, mesenchymal and stemness markers 
in spheroids derived from T88 and T93 cell cultures. Confocal microscopy images of 
immunofluorescence analysis of T88 and T93 cells performed with (A) Vimentin/ pan-
Cytokeratin, (B) N-/ E-Cadherin, (C) β-Catenin/ CD44, (D) Snail/ LGR5, (E) 
Nanog/ALDH1, and (F) Oct4/ Sox2 antibodies. 
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As shown in Figure 3.13, inhibition of GSK-3β by LiCl induced a 
downregulation of the expression of Vimentin and N-Cadherin 
mesenchymal markers (Fig. 3.13A and B) and of the EMT-TF Snail (Fig. 
3.13D). T88 and T93 cancer spheroids treated with LiCl stored the 
expression of E-Cadherin (Fig. 3.13B), however the hybridization signal of 
pan-Cytokeratin antibody was very low (Fig. 3.13A). Expression of CD44 
and β-Catenin proteins seemed to be quite similar in T88 and T93 spheroids 
after incubation with LiCl (Fig. 3.13C); while the expression of specific 
stem cell markers, such as Nanog, Oct4, Sox2, LGR5, and ALDH1 strongly 
decreased in response to GSK-3β inhibition and this effect was predominant 
in T93 cancer spheroids (Fig. 3.13D, E and F). 
 
To further investigate cell plasticity of T88 and T93 cell cultures, we 
disaggregated spheroids obtained by hanging drop assay, grown with or 
without LiCl; and cultivated them in adhesion and in the same conditions 
used for the original cell cultures (DMEM-F12 1:1 medium containing 10% 
FBS) (Fig. 3.14). These cells were again able to grow in adhesion; however, 
the number of cells attached to the plate was significantly lower when 
spheroids were treated with LiCl (Fig. 3.14B and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. T88 and T93 cell plasticity was affected by LiCl. T88 (A-B) and T93 (C-D) 
cells derived from disaggregation of cancer spheroids, which were treated with 30mM LiCl 
for 72 hours (B-D) or untreated (A-C). Images in bright field with x10 magnification (Scale 
bar 75µm). 
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4.1 Discussion 
We have performed an experimental system of primary mesenchymal 
colorectal cancer cell cultures, according to the hypothesis that EMT could 
be responsible for acquisition of cancer cell resistance to therapy. We set up 
a protocol to isolate primary colorectal cancer cell cultures from tumor 
tissues of patients affected by CRC. For molecular investigations, we chose 
two of these cultures because of their different morphologies; indeed T88 
looked more mesenchymal-like than T93 cells, which showed an epithelial-
like phenotype. First, we validated the cancer status of our cell cultures by 
performing MSI assay and karyotype analysis. We found that T93 cells had 
a CIN phenotype showing, in 95 % of the analysed karyotype, a 
translocation between the q arm of chromosome 20 and the q arm of 
chromosome 22, while T88 cells were characterized by a MSI-H phenotype 
with instability at mononucleotide markers NR21, NR24 and BAT40. 
By using molecular biology techniques, we demonstrated that T88 and T93 
cells expressed together epithelial (Cytokeratins and E-Cadherin) and 
mesenchymal (Vimentin and N-Cadherin) markers, and high levels of EMT-
TFs Twist and Snail. Since T88 and T93 cell cultures were isolated from 
adenocarcinomas, which are epithelial tumors, the expression of 
mesenchymal markers and EMT-TFs suggested that these cells were 
epithelial cells undergone EMT.  
In addition we demonstrated that T88 and T93 cells expressed stemness 
markers, such as Nanog, Oct4, Sox2, ALDH1 and LGR5. These results were 
in accordance with literature data indicating that EMT program induces the 
expression of stem cell specific genes, and might represent a source of 
cancer stem-like cells (Reya et al. 2001). 
EMT and its reverting process MET, are physiological process occurring 
during embryonic development and tissue remodelling, furthermore, it has 
been suggested that EMT is involved in cancer progression and metastasis 
in several tumours, including CRCs (Loboda et al. 2011).  
Since the multifunctional kinase GSK-3β plays an important role in cross 
talk between different pathways involved in CRCs development, we decided 
to study its role during EMT of CRC cells. To realize this aim, we incubated 
T88 and T93 cells with Lithium Chloride (LiCl). LiCl is the most studied 
among GSK-3β inhibitors and exerts its action by competing with Mg2+, a 
co-factor of this enzyme, and by activating Ser9 inhibitory phosphorylation 
of GSK-3β.  
After 10 days of incubation with LiCl, the expression of the EMT-TFs, 
Twist1 and Snail, and mesenchymal markers was down-regulated and the 
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transcription of E-Cadherin was increased, suggesting that the inhibition of 
GSK-3β induced a reversion of EMT program, and cells underwent MET. 
Interestingly COX2 that was overexpressed in both cell cultures, was also 
highly down-regulated after treatment with LiCl. According to these results, 
literature data indicate a strong association between COX2 expression and 
cancer progression and metastasis (Elzagheid et al. 2013).  
Furthermore, we performed wound healing assay and demonstrated that 
LiCl affected migration of T88 and T93 cells, which is a crucial feature in 
metastases development.  
Cancer stem cells and cancer stem-like cells play a key role in cancer 
progression and metastases, and they are probably responsible for both 
relapse and resistance to therapy (Gangemi et al. 2009, Fanali et al. 2014). 
It has been suggested that cancer cells, which are more undifferentiated and 
display stem cell like properties, are able to grow as spheres in suspension 
in a specific culture medium. Three-dimensional (3D) in vitro models have 
been used in cancer research as an intermediate model between in vitro 
cancer cell line cultures and in vivo tumor. Spherical cancer models 
represent major 3D in vitro models that have been described over the past 4 
decades. These models have gained popularity in cancer stem cell research 
using tumorospheres. They contribute to chemoresistance, radioresistance, 
tumorigenicity, invasion and migration studies. Several methods to isolate 
CSCs have been well described in literature, one of these is hanging drop 
assay (Weiswald et al. 2015). We performed hanging drop assay of T88 and 
T93 cell cultures showing that these cells were able to aggregate and form 
spheroids in suspension. We characterized these cancer spheroids at 
molecular level, by performing immunofluorescence analysis, and found 
that they stored the expression of both mesenchymal and epithelial markers, 
however the EMT-TF Snail showed a lower nuclear localization respect to 
the original T88 and T93 cell cultures grown in adhesion.  
We analysed the expression of a panel of stem cell biomarkers (Nanog, 
Oct4, Sox2, ALDH1 and LGR5), and demonstrated that T88 and T93 cancer 
spheroids expressed all these markers, with little differences between these 
two cultures.  
Furthermore, we investigated the effect of GSK-3β inhibition on cancer 
spheroids formation and demonstrated that LiCl induced T88 and T93 cells 
to lose the ability to form well-defined spheroids in suspension, especially 
T93 cells. According to this observation, after 72 hours of treatment with 
LiCl, the expression of stemness and mesenchymal markers was strongly 
reduced and this effect was predominant in T93 cancer spheroids. 
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Thus, we concluded that epithelial-mesenchymal primary colon cancer cells 
formed spherical aggregates in hanging drop assays indicating a 
dedifferentiated state that correlates with expression of 
undifferentiation/differentiation markers. LiCl incubation altered dynamic 
of spheres formation in hanging drop assays indicating differentiated state 
that again correlates with expression of undifferentiation/differentiation 
markers, specifically inducing downregulation of all mesenchymal and stem 
cell biomarker analysed.  
Since cellular plasticity is a crucial feature of cancer cells in metastasis 
development, we decided to test the ability of T88 and T93 cell cultures to 
switch from one phenotype to another. To this aim, we cultivated the cells 
derived from disaggregation of cancer spheroids grown for 72 hours with or 
without LiCl. These cells were again able to grow in adhesion like the 
original cultures. However, this ability was significantly affected in cells 
derived from spheroids treated with LiCl.  
As stated in the Introduction, GSK-3β can act as pro‑apoptotic factor 
negatively regulating Wnt signaling, by controlling the degradation of 
β‑catenin. On the other hand, it positively regulates NF-κB pathway by 
mediating the degradation of IκB, a central inhibitor of NF-κB, so inducing 
an anti‑apoptotic response (Beurel and Jope 2006). In colon and pancreatic 
cancer cells, GSK-3β activates a proliferative signal by activation of NF-
κB, and inactivation of GSK-3β inhibits NF-κB activity (Shakoori et al. 
2005, Shakoori et al. 2007). Interestingly, Snail, CD44, G3BP2, and YAP1 
are targets of Wnt5A, a gene involved in invasion and metastasis of many 
cancers that is regulated by NF-κB signaling pathway (Du and Geller 2010, 
Katoh and Katoh 2009). E‑ cadherin and its transcriptional repressor Snail 
orchestrate a functional cross regulation between Wnt and NF-κB pathways 
during EMT. Expression of Snail promotes E‑cadherin downregulation 
destroying epithelial organization and inducing mesenchymal phenotype of 
epithelial cells, that takes place together with upregulation of mesenchymal 
genes expression. E‑ cadherin and other cell adhesion components directly 
bind both β‑catenin and NF-κB, sequestering them into adherens junctions 
and therefore preventing the transcription of target genes (Conacci-Sorrell 
et al. 2002, Solanas et al. 2008). As recently described (Benoit et al. 2014), 
we suggest that GSK-3β inhibition could represent a good strategy targeting 
the cross regulation between these two pathways and may be a promising 
direction for future cancer therapy that needs to be better elucidated.  
Discussion and conclusion 
 
 80 
Specifically,  LiCl, a drug already used in clinical practices for treatment of 
bipolar disorders, could represent an alternative therapy in colon cancer care 
and/or able to sensitize cancer cells to chemo-radio-therapy, acting through 
downregulation of EMT-TFs  and specific stem cell biomarkers. 
Cell culture models obviously do not mimic the complex interaction that are 
found in the intestinal mucosa and a functional change in the cell cultures 
cannot tell us whether there will be the same effect in vitro. Nevertheless, 
cell cultures are used in an attempt to make complex systems simpler by 
isolating certain functions and investigate them in detail. From this point of 
view, we speculated that our cell culture could represent an interesting 
model to further investigate the molecular biology of mesenchymal CRC 
cells, clinical relevance of EMT in human CRC and the molecular basis of 
pharmacological resistance and metastasis. 
 
 
4.2 Conclusion 
We set up a protocol to isolate primary mesenchymal colorectal cancer cell 
cultures deriving from an EMT process of epithelial cancer cells. To our 
knowledge, there are no data in literature about primary colorectal cancer 
cells isolated from CRC patients, expressing both mesenchymal and 
epithelial markers and high level of EMT-TFs. We isolated primary cell 
cultures from different patients affected by CRCs; specifically we chose to 
analyze two of these cell cultures, named T88 and T93. T88 cells, that 
looked more mesenchymal-like, were characterized by a MSI-H phenotype, 
while T93 cells, that showed a more epithelial morphology, had a CIN 
phenotype. Molecular characterization of these cell cultures showed that 
they expressed both mesenchymal and epithelial markers, and genes specific 
of stem cells. This is in accordance with the features of EMT program that 
induces not only a mesenchymal phenotype but also stem cell like properties 
(Mani et al. 2008).  
We decided to study the effect of the inhibition of GSK-3β, by treating our 
cell cultures with Lithium Chloride (LiCl), since this kinase plays a crucial 
role in the cross talk between several molecular pathways involved in CRCs 
development. We demonstrated that LiCl was able to induce mesenchymal 
to epithelial reverting transition (MET) in T88 and T93 cells, and down-
regulated the expression of stem cell markers. 
EMT confers to the epithelial cells migratory and invasive properties, which 
are crucial features in metastatic process. T88 and T93 cancer cells showed 
high migration ability that, however, was significantly affected by LiCl. 
Discussion and conclusion 
 
 81 
In accordance with the expression of stem cell genes, T88 and T93 cell 
cultures were able to grow in suspension as spheres in a conditioned medium 
without serum, but they lost the ability to form well-defined spheroids in 
presence of LiCl. These cancer spheres expressed epithelial, mesenchymal 
and stem cell markers; however, treatment with LiCl induced a strong 
downregulation of the EMT-TF Snail, mesenchymal and stemness genes. 
Our study suggested that EMT could represent a common mechanism 
belonging to different CRC types, at molecular level. Indeed the inhibition 
of GSK-3β induced MET in both cell cultures; despite they were 
characterized by different pathways of genomic instability. We speculated 
that our cell cultures could be an interesting in vitro model to investigate the 
clinical relevance of EMT and the molecular basis of pharmacological 
resistance and metastasis, in human CRCs (Costabile et al. 2015).  
Cellular plasticity plays an important role in cancer development and 
progression; cancer cells can switch from one phenotype to another and 
acquire resistance to therapy (Vicente-Dueñas et al. 2008, Doherty et al. 
2016). 
We proposed that LiCl might be able to sensitize cancer cells to therapy, by 
downregulating EMT-TFs and stemness genes, and affecting cell plasticity 
and migration. Thus, GSK-3β and LiCl could be an eligible target and a 
potential drug to develop therapy for CRCs care, respectively.  
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